Liraglutide (n=10)
Clinical Trial Outcomes with Monotherapy The REDEFINE 1 trial demonstrated that cagrilintide monotherapy at the 4.5 mg maintenance dose produced mean body weight reductions of approximately 10.8% from baseline after 32 weeks of treatment [4]
, , ,
Quantitative PCR assays were performed using 480 SYBR Green Master reagent mix (Roche Life Science, 4707516001, murine probes) or TaqMan assays (human ETC genes) on a real-time fluorescence qPCR instrument (LightCycler 480II, Roche Life Science)
DailyMed prescribing information for Wegovy lists nausea, vomiting, diarrhea, abdominal pain, constipation, dyspepsia, flatulence, gastroesophageal reflux disease, gastritis, and other gastrointestinal reactions among reported adverse reactions
Indian J Surg 85 , 14941495 (2023)